desethylamiodarone has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antus, C; Bognar, R; Bognar, Z; Cseh, AM; Fekete, K; Gallyas, F; Ramadan, FHJ; Sumegi, B; Tapodi, A | 1 |
| Bognar, R; Bognar, Z; Gallyas, F; Kovacs, D; Ramadan, FHJ; Szabo, A; Takatsy, A | 1 |
2 other study(ies) available for desethylamiodarone and B16 Melanoma
| Article | Year |
|---|---|
Amiodarone's major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Skin Neoplasms | 2020 |
Involvement of Mitochondrial Mechanisms in the Cytostatic Effect of Desethylamiodarone in B16F10 Melanoma Cells.
Topics: Amiodarone; Animals; Apoptosis; Apoptosis Inducing Factor; Cell Proliferation; Cytochromes c; Cytostatic Agents; Energy Metabolism; Humans; Lung; Melanoma, Experimental; Membrane Potential, Mitochondrial; Mice; Mitochondria; Oxygen Consumption; Permeability; Reactive Oxygen Species | 2020 |